U.S. Contraceptive Market Size to Hit Around USD 15.89 Bn By 2032
The U.S. contraceptive market size was exhibited at USD 9.6 billion in 2022 and is projected to hit around USD 15.89 billion by 2032, growing at a CAGR of 5.17% during the forecast period 2023 to 2032.
Key Takeaways:
U.S. Contraceptive Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 10.1 Billion |
| Market Size by 2032 | USD 15.89 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 5.17% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Church & Dwight Co. Inc.; Reckitt Benckiser Group Plc; Veru, Inc.; Organon Group Of Companies; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; The Cooper Companies, Inc.; Mayer Laboratories, Inc.; Agile Therapeutics; TherapeuticsmMD, Inc.; Bayer Ag; Afaxys, Inc.; Mithra Pharmaceuticals; Abbvie |
Increase in the use of modern contraceptives and rise in awareness among adolescents and the young population about sexual health and family planning are key factors that driving the U.S. market growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.
Development, approval, and commercialization of new, more effective, and long-acting reversible contraceptive methods are expected to drive the industry scale during the forecast period. For instance, Agile Therapeutics developed a hormonal patch, Twirla, which was introduced in the U.S. in the fourth quarter of 2020. The launch of generic and low-cost drugs and devices has led to an increase in the demand for contraceptives by teenagers as well. Furthermore, the demand for nonhormonal contraceptives in the U.S. is increasing since they eliminate the risk of adverse effects associated with hormonal imbalance in the body.
Improving access to Family Planning and Reproductive Health (FP/RH) services can have a positive impact on the economy as the number of unintended pregnancies and maternal deaths would be limited. The U.S. government supports global FP/RH efforts which is one of the largest distributors and purchasers of contraceptives.
In 29 U.S. states, insurers are required to provide a full range of coverage for FDA-approved contraceptive methods for women. In 12 states, over-the-counter contraceptives are covered; however, insurers may require a prescription from the beneficiary. In 20 states and the District of Columbia, insurers are required to cover an extended supply of contraceptives at one time.
The COVID-19 pandemic has significantly impacted the U.S. healthcare sector. The contraceptives market is majorly dependent on physician-prescribed and physician-administered products. Due to restrictions on visiting physician offices without an emergency the demand for contraceptive products was low during the first few months of the pandemic. Telehealth services and virtual consultations were recommended for contraceptive screening and counseling.
Furthermore, demand for nonhormonal contraceptives in young women is expected to increase as they want to avoid risks associated with hormonal contraceptives. Newly developed products, such as nonhormonal vaginal rings, diaphragms, and innovative condoms, are expected to aid the growth of the nonhormonal products segment during the forecast period.
Product Insights
The U.S. contraceptive market has been segmented into pills, Intrauterine Devices (IUD), condoms, vaginal ring, subdermal implant, injectable, and others. Subdermal implants segment is expected to witness the highest growth with a CAGR of 9.63% over the forecast period. In 2022, Oral contraceptives pills accounted for the largest market share of 38.44% due to large number of products introduced by several market players, a high success rate (99.0% when used perfectly), and convenience in using oral pills for contraception. These medicines are available only via a gynecologist’s prescription and can be used for other conditions as well, such as dysmenorrhea, amenorrhea, hypermenorrhea, endometriosis, and others. The popularity of pills among young women in the U.S. can be attributed to safety and ease of administration.
The popularity of male condoms is high among young individuals due to easy availability, economic pricing, and added advantage of protection against STDs. Moreover, the availability of a vast range of variants in various sizes, flavors, textures, and thickness helps enhance sexual experience of users. In April 2017, Church & Dwight Co., Inc. launched a new range of condoms, XOXO that were available in gender-neutral colors. The product is designed to appeal to women and provide enhanced sexual experience.
Furthermore, the acceptance of long-acting reversible contraceptives has significantly improved in the last decade. Intrauterine devices, injectables, and vaginal rings are expected to witness sustainable growth during the forecast period. The market is driven by cost-effectiveness and longer duration of product life. The launch of new products and ease of use of vaginal rings are factors expected to increase demand for such methods of birth control. TherapeuticsMD Inc.’s Annovera—a reusable silicone ring that provides protection for up to 1 year from unintended pregnancy gained FDA approval & market exclusivity of 5 years as a new chemical entity in September 2018 and was be launched commercially in the first quarter of 2020.
Key Companies & Market Share Insights
The regional market is highly competitive due to the presence of several companies. Most of the companies are undertaking strategic initiatives, such as investments in R&D for developing innovative products and to gain a competitive edge over others. In February 2020, Afaxys, Inc. and TherapeuticsMD, Inc. signed an agreement to increase access to Annovera in the U.S. public healthcare system. In July 2020, TherapeuticsMD, Inc. entered into an agreement with Nurx—an online company for women’s health-for increasing its access to Annovera. High investments by prominent companies for the commercialization of effective and long-term reversible contraceptives have increased the awareness levels about these products. Some of the prominent companies in the U.S. contraceptive market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Contraceptive market.
By Product
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisorInternal Database
1.3.3 SSecondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.2 Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Product
2.3 Competitive Insights
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/Ancillary market outlook
3.2 Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Rapid technological advancements
3.2.1.2 Increasing initiatives by social organizations to improve access to condoms
3.2.1.3 Rising publicly funded family planning services
3.2.2 Market restraint analysis
3.2.2.1 Increasing geriatric population and rising prevalence of infertility
3.2.2.2 Adverse effects associated with the use of contraceptive drugs and devices
3.3 Business Environment Analysis Tools
3.3.1 PESTEL analysis
3.3.1.1 Political & legal landscape
3.3.1.2 Economic & social landscape
3.3.1.3 Technological landscape
3.3.2 Porter’s Five Forces Analysis
3.3.2.1 Competitive rivalry - High
3.3.2.2 Bargaining power of suppliers - Moderate
3.3.2.3 Bargaining power of buyers - Moderate
3.3.2.4 Threat of new entrants - High
3.3.2.5 Threat of substitutes - Moderate
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Pipeline Analysis
3.6 Regulatory & Reimbursement Framework
3.6.1 Regulatory Scenario
3.6.2 Reimbursement Framework
3.7 Impact of COVID - 19: Qualitative Analysis
Chapter 4 U.S. Contraceptive Market: Product Analysis
4.1 U.S. Contraceptive Market Share Analysis, 2022- 2032
4.2 U.S. Contraceptive Product Market: Segment Dashboard
4.3 Market Size & Forecasts and Trend Analysis, 2020 to 2032 for the Product Segment
4.3.1 Pills
4.3.1.1 Pills market, 2020 - 2032
4.3.2 Intrauterine Device (IUD)
4.3.2.1 Intrauterine device market, 2020 - 2032
4.3.2.2 Hormonal IUD
4.3.2.2.1 Hormonal IUD market, 2020 - 2032
4.3.2.3 Nonhormonal IUD
4.3.2.3.1 Nonhormonal IUD market, 2020 - 2032
4.3.3 Condoms
4.3.3.1 Condoms market, 2020 - 2032
4.3.3.2 Male Condoms
4.3.3.2.1 Male Condoms market, 2020 - 2032
4.3.3.3 Female Condoms
4.3.3.3.1 Female Condoms market, 2020 - 2032
4.3.4 Vaginal Ring
4.3.4.1 Vaginal ring market, 2020 - 2032
4.3.5 Subdermal Implants
4.3.5.1 Subdermal implants market, 2020 - 2032
4.3.6 Injectable
4.3.6.1 Injectable market, 2020 - 2032
4.3.7 Others
4.3.7.1 Others market, 2020 - 2032
Chapter 5 Competitive Analysis
5.1 Recent Developments & Impact Analysis, by Key Market Participants
5.2 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players)
5.3 Major Deals & Strategic Alliances Analysis
5.3.1 Mergers & acquisitions and joint ventures
5.3.2 Licensing & partnership and technology collaborations
5.4 Vendor Landscape
5.4.1 List of Players in the U.S. Contraceptive Market
5.4.2 Company Market Position Analysis
5.5 Company Profiles
5.5.1 Church & Dwight Co., Inc.
5.5.1.1 Company overview
5.5.1.2 Financial performance
5.5.1.3 Product benchmarking
5.5.1.4 Strategic initiatives
5.5.1.5 SWOT analysis
5.5.2 Reckitt Benckiser Group plc
5.5.2.1 Company overview
5.5.2.2 Financial performance
5.5.2.3 Product benchmarking
5.5.2.4 Strategic initiatives
5.5.2.5 SWOT analysis
5.5.3 Veru, Inc.
5.5.3.1 Company Overview
5.5.3.2 Financial performance
5.5.3.3 Product benchmarking
5.5.3.4 Strategic initiatives
5.5.3.5 SWOT Analysis
5.5.4 Organon Group of Companies
5.5.4.1 Company overview
5.5.4.2 Financial performance
5.5.4.3 Product benchmarking
5.5.4.4 Strategic initiative
5.5.4.5 SWOT analysis
5.5.5 Pfizer, Inc.
5.5.5.1 Company overview
5.5.5.2 FINANCIAL PERFORMANCE
5.5.5.3 Product benchmarking
5.5.5.4 Strategic initiatives
5.5.5.5 SWOT analysis
5.5.6 Teva Pharmaceutical Industries Ltd.
5.5.6.1 Company overview
5.5.6.2 Financial performance
5.5.6.3 Strategic initiatives
5.5.6.4 SWOT analysis
5.5.7 The Cooper Companies, Inc.
5.5.7.1 Company overview
5.5.7.2 Financial performance
5.5.7.3 Product benchmarking
5.5.7.4 Strategic initiative
5.5.7.5 SWOT analysis
5.5.8 Mayer Laboratories, Inc.
5.5.8.1 Company overview
5.5.8.2 Product benchmarking
5.5.9 Agile Therapeutics
5.5.9.1 Company overview
5.5.9.2 Financial performance
5.5.9.3 Product benchmarking
5.5.9.4 Strategic initiatives
5.5.9.5 SWOT analysis
5.5.10 TherapeuticsMD, Inc.
5.5.10.1 Company overview
5.5.10.2 Financial performance
5.5.10.3 Product benchmarking
5.5.10.4 Strategic initiative
5.5.10.5 SWOT analysis
5.5.11 Bayer AG
5.5.11.1 Company overview
5.5.11.2 Financial performance
5.5.11.3 Product benchmarking
5.5.11.4 Strategic initiatives
5.5.11.5 SWOT analysis
5.5.12 Afaxys, Inc.
5.5.12.1 Company overview
5.5.12.2 Product benchmarking
5.5.12.3 Strategic initiatives
5.5.12.4 SWOT analysis
5.5.13 Mithra Pharmaceuticals
5.5.13.1 Company overview
5.5.13.2 Financial performance
5.5.13.3 Product benchmarking
5.5.13.4 Strategic initiatives
5.5.13.5 SWOT analysis
5.5.14 Abbvie
5.5.14.1 Company overview
5.5.14.2 Financial performance
5.5.14.3 Product benchmarking
5.5.14.4 Strategic initiatives
5.5.14.5 SWOT analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers